Press Release: Sanofiâs venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Sanofiâs venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy...
.css-116336j{justify-self:center;color:#000;grid-area:brand;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;margin-left:-4px;margin-right:-4px;}@media (min-width:1280px){.css-116336j{justify-self:auto;}}@media (min-width:0px){.panelIsOpen .css-116336j{display:none;}}@media (min-width:768px){.panelIsOpen .css-116336j{display:none;}}@media (min-width:1280px){.panelIsOpen .css-116336j{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}}.css-116336j:focus-visible{outline:rgba(60, 33, 123, 1.00);outline-style:solid;outline-width:4px;border-radius:calc(8px / 2);}.css-1y69bg3{font-size:5rem;}.panelIsOpen .css-1y69bg3{display:none;}@media (min-width:1280px){.panelIsOpen .css-1y69bg3{display:block;}}.css-e118jn-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.7142857142857142rem;font-size:1.2rem;margin-left:4px;margin-top:4px;margin-right:4px;margin-bottom:8px;height:auto;font-size:5rem;}.panelIsOpen .css-e118jn-MuiSvgIcon-root{display:none;}@media (min-width:1280px){.panelIsOpen .css-e118jn-MuiSvgIcon-root{display:block;}}Sanofi.css-1gxp1dt{grid-area:search;-webkit-transition:opacity 0.3s ease-in-out;transition:opacity 0.3s ease-in-out;opacity:0;}@media (min-width:0px){.css-1gxp1dt{display:block;margin-left:0px;margin-right:-12px;}}@media (min-width:768px){.css-1gxp1dt{display:block;margin-left:0px;margin-right:-12px;}}@media (min-width:1280px){.css-1gxp1dt{display:none;margin-left:-22px;margin-right:-22px;}}@media (min-width:0px){.panelIsOpen .css-1gxp1dt{display:none;}}@media (min-width:1280px){.panelIsOpen .css-1gxp1dt{display:block;}}.css-xr4wbu{justify-self:center;color:#000;display:block;}@media (min-width:1280px){.css-xr4wbu{justify-self:auto;}}.css-xr4wbu:focus-visible{outline:solid rgba(60, 33, 123, 1.00) 4px;outline-offset:0;}@media (min-width:0px){.css-xr4wbu:focus-visible{border-radius:100%;}}@media (min-width:768px){.css-xr4wbu:focus-visible{border-radius:100%;}}@media (min-width:1280px){.css-xr4wbu:focus-visible{border-radius:100%;}}.css-xesgy4-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.7142857142857142rem;font-size:1.2rem;}.css-1syo2p5{display:block;grid-area:panel;position:absolute;top:1;left:-16px;overflow-x:hidden;overflow-y:scroll;height:100%;width:calc(100% + (16px) * 2);background-color:#fff;}.panelIsOp